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Abstract
Background: A number of single nucleotide polymorphisms (SNPs) have been associated with broadband
ultrasound attenuation (BUA) and speed of sound (SOS) as measured by quantitative ultrasound (QUS) at the
calcaneus in the Framingham 100K genome-wide association study (GWAS) but have not been validated in
independent studies. The aim of this analysis was to determine if these SNPs are associated with QUS
measurements assessed in a large independent population of European middle-aged and elderly men. The
association between these SNPs and bone mineral density (BMD) measured using dual-energy X-ray
absorptiometry (DXA) was also tested.
Methods: Men aged 40-79 years (N = 2960) were recruited from population registers in seven European centres
for participation in an observational study of male ageing, the European Male Ageing Study (EMAS). QUS at the
calcaneus was measured in all subjects and blood was taken for genetic analysis. Lumbar spine (LS), femoral neck
(FN) and total hip (TH) BMD were measured by DXA in a subsample of 620 men in two centres. SNPs associated
with BUA or SOS in the Framingham study with p < 10-4 were selected and genotyped using SEQUENOM
technology. Linear regression was used to test for the association between SNPs and standardised (SD) bone
outcomes under an additive genetic model adjusting for centre. The same direction of effect and p < 0.05
indicated replication.
Results: Thirty-four of 38 selected SNPs were successfully genotyped in 2377 men. Suggestive evidence of
replication was observed for a single SNP, rs3754032, which was associated with a higher SOS (b(SD) = 0.07, p =
0.032) but not BUA (b(SD) = 0.02, p = 0.505) and is located in the 3’UTR of WDR77 (WD repeat domain 77) also
known as androgen receptor cofactor p44. A single SNP, rs238358, was associated with BMD at the LS (b(SD) =
-0.22, p = 0.014), FN (b(SD) = -0.31,p = 0.001) and TH (b(SD) = -0.36, p = 0.002) in a locus previously associated
with LS BMD in large-scale GWAS, incorporating AKAP11 and RANKL.
Conclusions: We found suggestive evidence of association between a single SNP located in the 3’UTR of WDR77
with calcaneal ultrasound parameters. The majority of SNPs, associated with QUS parameters in the Framingham
Study, were not replicated in an independent population sample of European men.
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Background
Quantitative ultrasound (QUS) of the calcaneus is a
widely used method for the assessment of bone health.
Prospective studies confirm a positive relationship
between a decline in ultrasound parameters (broad band
ultrasound attenuation [BUA] and speed of sound
[SOS]) and fracture risk [1-3].
Genetic factors are important determinants of calca-
neus ultrasound parameters. Family and twin studies
have shown that heritability of BUA and SOS at the cal-
caneus is 52-59% and 45-75%, respectively [4-7]. The
proportion of population variation in ultrasound para-
meters explained by genetic factors is similar in men and
women, though there is also evidence suggesting a gen-
der-specific component to the overall genetic variance
[8]. Genome-wide association studies (GWAS) are now
widely used for identifying genetic associations with com-
plex traits. During the past three years, a number of
GWAS exploring various bone phenotypes have been
published. The majority of these studies have focused on
bone mineral density (BMD); however, a number of sin-
gle nucleotide polymorphisms (SNPs) have also been
reported in association with BUA and SOS in the Fra-
mingham 100K GWAS, the first published GWAS of
bone phenotypes [9]. These findings remain to be vali-
dated in independent population samples.
Our study aimed to validate the most significant SNP
associations with BUA and SOS from the Framingham
100K GWAS utilizing an independent population of
middle-aged and elderly men recruited in the European
Male Ageing Study (EMAS). We also investigated, in a
subgroup of men, the association between these SNPs
and BMD as assessed using dual energy x-ray absorptio-
metry (DXA).
Methods
Study Participants
Men aged 40-79 years were recruited into EMAS from
population registers in 8 European centres (Manchester,
UK; Leuven, Belgium; Tartu, Estonia; Lodz, Poland;
Szeged, Hungary; Florence, Italy; Santiago de Compos-
tela, Spain; Malmö, Sweden). Subjects were invited to
participate by letter of invitation and those who agreed
were invited to attend for a more comprehensive assess-
ment including a blood sample for genetic analysis and
QUS at the calcaneus. A subsample of subjects in two
centres (Manchester and Leuven) had BMD measured
by DXA at the lumbar spine (LS), femoral neck (FN)
and total hip (TH). Participants were excluded from the
analysis if they reported that they themselves or one of
their parents or grandparents was born outside Europe
or North America, or if they reported use of anti-osteo-
porotic medications or systemic glucocorticoids. Ethical
approval in each centre was obtained in accordance
with local practice and requirements, and subjects gave
informed consent; approval for the genetic analysis
described here was obtained for seven of the eight cen-
tres (all centres except for Malmö, Sweden). Analysis
was restricted therefore to subjects from these seven
centres.
Anthropometric and Lifestyle Measurements
Weight to the nearest 10 g and height to the nearest
mm were measured using calibrated scales stadiometer.
Body mass index (BMI) was calculated as weight divided
by height squared (kg/m2). Cigarette smoking was
assessed by standard questionnaire. Physical activity was
measured using the physical activity scale for the elderly
(PASE) [10].
Bone Assessments
QUS
Heel ultrasound measurements were made at the left
calcaneus, using the Sahara Clinical Sonometer (Hologic,
Bedford, Massachusetts, USA), in all centres following a
standardized protocol. Each centre used the same
machine model, which was calibrated daily with the
physical phantom provided by the manufacturer. Out-
puts included broadband ultrasound attenuation (BUA)
(dB/MHz) and speed of sound (SOS) (m/s). Quality con-
trol (QC) was performed in each centre following the
instructions of the manufacturer. All QC results were
compiled and checked for stability throughout the study
in Leuven. To ascertain the short-term precision of the
method in this population, duplicate measurements
were performed in 20 randomly selected subjects in
Leuven. The in vivo coefficient of variation (CV) was
2.8% and 0.3% for BUA and SOS, respectively. Repeat
measurements (N = 10) were performed on a roving
phantom at each of the eight centres. Standardized CVs
for within machine variability ranged by centre from
1.0% to 5.6% for SOS and from 0.7% to 2.7% for BUA.
Standardized CVs for between machine variability were
4.8% and 9.7% for BUA and SOS, respectively.
DXA
Bone densitometry scans were carried out in the Man-
chester and Leuven subsets of EMAS. Both sites used
DXA QDR 4500A devices of the same manufacturer
(Hologic, Inc, Waltham, MA, USA). BMD (g/cm2) was
measured at the LS (L1 to L4) and proximal femur (FN
and TH). All scans and measurements were performed
by trained and experienced DXA technicians. The Holo-
gic Spine Phantom was scanned daily to monitor the
device performance and long-term stability. The preci-
sion of these measurements in the LS, FN and TH were
0.57%, 1.28% and 0.56% in Leuven, and 0.97%, 1.29%
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and 0.97% in Manchester, respectively. Both devices
were cross-calibrated with the European Spine Phan-
tom [11].
Genotyping and Quality Control
DNA Extraction
DNA was extracted from leucocytes in venous blood
samples using standard phenol-chloroform extraction
and stored at -80°C prior to further analysis.
SNPs Selection
The data from the Framingham 100K GWAS were
extracted from the database of Genotypes and Pheno-
types (dbGaP) (http://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?id=phs000007) in January 2008.
Stringent quality control was applied to the data; call
rate ≥ 95% and Hardy-Weinberg equilibrium (HWE)
p > 10-4. Subsequently, SNPs with minor allele frequency
(MAF) ≥5% associated with BUA or SOS (p < 10-4) in the
100K Framingham GWAS based on multivariable adjusted
(age, height, BMI, smoking, physical activity, estrogen
therapy) additive generalized estimating equation (GEE)
model were selected for genotyping.
For the gene (±10 Kb flanks) showing evidence of
replication in EMAS, additional pair-wise tag SNPs
(r2≥0.8, MAF ≥5%) were selected using HapMap CEPH
SNP data (http://www.hapmap.org) and Tagger imple-
mented in Haploview 4.0 [12].
Genotyping and Quality Control
SEQUENOM MassARRAY technology was used for
genotyping all SNPs following the manufacturer’s
instructions (http://www.sequenom.com). Sample and
assay quality control thresholds were set to 90%. Allele
frequencies were tested for deviation from HWE in the
total population and the SNPs with p ≤ 0.05 were
excluded from analysis. STATA (9.2) was used for cal-
culating allele frequencies and quality control.
Statistical Analysis
The outcome variables (BUA, SOS and BMD at the LS,
FN and TH) were standardised (z-scores). The associa-
tion between the SNPs and the standardised outcome
variables was tested using linear regression under an
additive genetic model with adjustments made for cen-
tre. Multivariable analysis was also conducted to further
adjust for age, BMI, height, smoking (both current and
ever) and physical activity in keeping with the Framing-
ham Study. All analyses were performed using PLINK
(Version 1.07) [13]. Results are presented as mean
change in outcome (b coefficient) with 95% confidence
intervals (95%CI) for each copy of the minor allele. The
criteria for replication were that a SNP needs to be asso-
ciated with ultrasound measures with p < 0.05 with the
effect estimate (b coefficient) in the same direction as
reported in the Framingham study. The interaction
between SNP and centre was tested for the SNPs asso-
ciated with the outcome variables to test for between
centre heterogeneity using STATA (9.2).
The statistical power was calculated using Quanto
v1.2.3 software [14].
Results
Subject Characteristics
Of the 2960 men recruited from the seven centres, 2653
consented to participate in genetic analysis, 215 of
which were excluded due to failing sample quality con-
trol (n = 101), reporting at least one of their parents or
grandparents being born outside Europe or North
America (n = 17) or reporting use of anti-osteoporotic
medications or systemic glucocorticoids (n = 97). In
total, 2438 men, mean (±SD) age 60 (±11) years old,
were included in the analysis of which 2377 had QUS
performed. BMD analysis was performed in a subset of
620 subjects. Mean values for BMD and QUS para-
meters are presented in Table 1. BUA and SOS were
highly correlated (r2 = 0.81, p < 0.001).
Power of Study
For BUA (mean ± SD = 80.1 ± 19.1 dB/MHz) and SOS
(mean ± SD = 1550.9 ± 34.5 m/s); with 5% type I error,
MAFs of 0.05-0.45, and 2377 individuals, there was 80%
power to detect differences of greater than 0.2 SD for
MAF = 0.05 and 0.1 SD for MAF = 0.45 under an addi-
tive genetic model. For BMD at the LS (mean ± SD =
1.06 ± 0.18 g/cm2), FN (mean ± SD = 0.81 ± 0.13 g/
cm2) and TH (mean ± SD = 1.01 ± 0.14 g/cm2); with
5% type I error, MAFs of 0.05-0.45, and 620 individuals,
there was 80% power to detect differences of greater
than 0.4 SD for MAF = 0.05 and 0.2 SD for MAF = 0.45
under an additive genetic model.
Genotyping
Thirty-eight SNPs associated with BUA (19 SNPs) and/
or SOS (26 SNPs) in the Framingham study with p ≤
10-4 were selected. All SNPs associated with BUA with
p ≤ 10-4 were also associated with SOS with p < 0.05,
and vice versa. The details of the selected SNPs are
shown in Additional file 1: Supplementary Table S1.
Four SNPs (rs10513725, rs1936473, rs2108167 and
rs4954265) failed genotyping. All remaining 34 SNPs
were successfully genotyped and passed quality control.
In addition, 4 SNPs (rs1891756, rs1264913,
rs12040764 and rs3754032) which tag a gene, WDR77,
showing evidence of replication, and its 10 Kb flanking
region were selected for genotyping. One of these SNPs,
rs12040764, failed genotyping; the others were success-
fully genotyped and passed quality control. The
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successfully genotyped SNPs gave 80% coverage of the
SNPs with a MAF of more than 5% in WDR77 and its
10 kb flanking region (chr1, 111774036-111803353).
Genetic Association Analysis
QUS
The results for BUA and SOS are shown in Table 2.
None of the SNPs were associated with BUA in EMAS
whereas a single SNP, rs3754032, was associated with
SOS. This SNP, which was associated with a higher SOS
(b(SD) (95% CI) =0.07 (0.01, 0.13), p = 0.032) in our
study, was associated with higher levels of both BUA (p
= 8.75 × 10-5) and SOS (p = 0.01) in the Framingham
study. In our study, no significant association was
observed between rs3754032 and BUA (b(SD) (95%CI)
=0.02 (-0.04, 0.08), p = 0.505). In order to account for
the number of independent SNPs (r2<0.8) tested (N =
31), SNP associations would need to reach a p-value of
<0.0016 to achieve statistical significance therefore the
association between rs3754032 and SOS should be
considered suggestive of replication. The regional link-
age disequilibrium (LD) plot for rs3754032 is shown in
Figure 1.
After further adjustment for age, BMI, height, smoking
and physical activity; although the estimated effect of
rs3754032 on SOS did not significantly alter, the p value
was slightly increased (b(SD) (95%CI) =0.06 (-0.01,
0.12), p = 0.085).
The SNP rs3754032 is located in WDR77, therefore
tag SNPs for WDR77 and its 10 Kb flanking regions
were subsequently genotyped. However, no significant
associations between the tag SNPs in WDR77
(rs1891756 and rs1264913) and ultrasound measures
were observed.
DXA
A single SNP, rs238358, on chromosome 13 was asso-
ciated with BMD at LS (b(SD) (95%CI) =-0.22 (-0.44,
-0.06), p = 0.014), FN (b(SD) (95%CI) =-0.31 (-0.54,
-0.15), p = 0.001) and TH (b(SD) (95%CI) =-0.36 (-0.50,
-0.14), p = 0.002). However, this SNP was not associated
with BMD in the Framingham study. After further
adjustment for age, BMI, height, smoking and physical
activity; rs238358 was still suggestively associated
with BMD at LS (b(SD) (95%CI) =-0.22 (-0.39, -0.06),
p = 0.025), FN (b(SD) (95%CI) =-0.31 (-0.46, -0.08),
p = 0.004) and TH (b(SD) (95%CI) =-0.29 (-0.43, -0.07),
p = 0.003). The regional LD plot for rs238358 is shown
in Figure 2.
Discussion
In this study we attempted to validate findings from the
Framingham 100K GWAS study by testing the associa-
tion of the most significantly associated SNPs (p < 1 ×
10-4), after applying stringent quality control criteria,
with BUA and SOS ultrasound measures at the calca-
neus in an independent sample of 2377 unrelated Eur-
opean men. Evidence of replication was observed for a
single SNP, rs3754032.
This SNP which was highly associated with BUA and
modestly associated with SOS in the Framingham study
was only associated with SOS in EMAS. The association,
however, does not remain significant if corrected for
multiple testing and should be considered suggestive of
replication.
The SNP rs3754032 is located on chromosome 1, in
the 3’UTR of WDR77 (WD repeat domain 77) also
known as androgen receptor cofactor p44. The andro-
gen receptor activates transcription of different target
genes in response to androgens [15,16], which have ana-
bolic effects on male bone metabolism. Acute onset of
androgen deficiency such as surgically induced hypogo-
nadism or pharmacological androgen deprivation ther-
apy causes rapid bone loss and increases risk of fracture
in men [17]. Androgen receptor cofactor p44 is one of a
number of cofactors which increases androgen receptor
transcriptional activities in the nucleus. It also acts as a
splicing associated factor in the cytoplasm [15,16].
Four other genes are also located in this region of
chromosome 1 including ADORA3 (adenosine A3 recep-
tor), OVGP1 (oviductal glycoprotein 1), ATP5F1 (ATP
Table 1 Subject Characteristics; DXA and QUS parameters
Florence Leuven Lodz Manchester Santiago Szeged Tartu All Centres
QUS N = 398 N = 328 N = 369 N = 337 N = 336 N = 348 N = 261 N = 2377
BUA (dB/
MHz)
77.05 (17.71) 82.43 (17.63) 79.90 (18.28) 87.62 (17.46) 84.00 (21.34) 71.09 (18.92) 79.30 (17.75) 80.09 (19.12)
SOS (m/s) 1542.32
(32.97)
1561.91
(31.66)
1547.46
(32.66)
1560.54
(34.51)
1557.86
(39.74)
1543.42
(30.09)
1543.54
(32.94)
1550.89
(34.53)
DXA BMD (g/cm2) - N = 328 - N = 292 - - - N = 620
Lumbar spine - 1.04 (0.17) - 1.07 (0.19) - - - 1.06 (0.18)
Femoral neck - 0.80 (0.12) - 0.82 (0.14) - - - 0.81 (0.13)
Total hip - 1.01 (0.14) - 1.02 (0.15) - - - 1.01 (0.14)
Data are shown in mean (standard deviation). QUS: Quantitative ultrasound, BUA: Broadband ultrasound attenuation, SOS: Speed of sound, DXA: Dual energy
X-ray absorptiometry, BMD: Bone mineral density.
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synthase B chain) and CHIA (chitinase, acidic); and
SNPs in this region are in moderate LD with rs3754032
(Figure 1). Adenosine A3 receptor is a cell surface
receptor that mediates part of the anti-inflammatory
effects of adenosine [18]. Interestingly, studies in rat
suggest that adenosine A3 receptor agonists can
preserve bone mass in adjuvant induced arthritis [18]
and prevent bone destruction in osteoarthritis [19]. We
did not find any evidence in the literature linking the
other three genes (OVGP1, ATP5F1 and CHIA) and
bone metabolism. Whilst WDR77 represents a good
candidate, we found no association between other SNPs
within this gene and ultrasound parameters suggesting a
single independent effect. Further work is required to
validate this association in a large cohort and to deter-
mine the causal effect in this region.
The majority of the SNP associations with BUA and
SOS in the Framingham study were not replicated in
our population. Lack of replication could be due to a
number of factors. First of all, the two populations dif-
fered in geographical location and gender; the Framing-
ham study (Massachusetts, USA) included 1141 subjects
Table 2 Characteristics of the SNPs and their association with BUA and SOS
Adjusted for centre Adjusted for centre, age, BMI,
height,
smoking and PASE score
BUA SOS BUA SOS
Chr Position SNP Alleles MAF (%) Nearest Gene within 500 kb b (SD) p b (SD) p b (SD) p b (SD) p
1 55553409 rs1807871 T > C 13.1 USP24 0.00 0.949 0.00 0.988 -0.02 0.645 0.00 0.949
1 92085352 rs2799516 G > A 9.0 TGFBR3 0.04 0.455 0.05 0.347 0.02 0.694 0.04 0.386
1 92099224 rs2046737 C > T 8.5 TGFBR3 0.06 0.231 0.06 0.240 0.05 0.339 0.06 0.267
1 111784127 rs3754032 T > A 26.0 WDR77 0.02 0.505 0.07 0.032 0.01 0.665 0.06 0.085
2 70027133 rs10496176 T > C 15.4 MXD1 0.03 0.440 0.01 0.874 0.02 0.619 0.00 0.950
2 82913481 rs10496276 T > G 19.2 0.02 0.638 0.01 0.696 0.00 0.944 0.00 0.940
2 118250857 rs1433527 C > A 45.3 DDX18 -0.04 0.110 -0.04 0.211 -0.05 0.081 -0.03 0.262
2 135824309 rs10496734 G > A 14.9 ZRANB3 -0.04 0.363 -0.03 0.447 -0.06 0.172 -0.06 0.139
2 158955976 rs2251471 T > C 6.7 CCDC148 0.09 0.123 0.12 0.027 0.10 0.060 0.14 0.012
3 30344099 rs1587126 A > C 33.7 TGFBR2 0.01 0.769 -0.01 0.665 -0.01 0.856 -0.02 0.496
3 99203733 rs1492053 G > A 37.0 GABRR3 0.00 0.963 0.00 0.909 0.01 0.704 0.01 0.674
3 163243925 rs10513577 T > C 31.0 0.00 0.991 0.01 0.773 0.02 0.559 0.03 0.320
3 163273126 rs1033059 A > G 31.0 0.00 0.943 0.01 0.815 0.02 0.588 0.03 0.339
3 163310228 rs951937 T > A 25.6 -0.02 0.568 0.00 0.975 -0.01 0.873 0.01 0.665
4 9933258 rs9291683 G > A 46.8 ZNF518B 0.04 0.171 0.04 0.168 0.03 0.334 0.03 0.245
4 57967285 rs10517393 G > T 22.8 IGFBP7 0.01 0.795 -0.03 0.341 0.02 0.481 -0.02 0.639
4 132163115 rs2055391 C > T 8.4 -0.01 0.920 0.00 0.996 0.01 0.789 0.01 0.800
4 182246126 rs7659755 A > G 18.3 -0.02 0.534 -0.04 0.225 -0.01 0.889 -0.03 0.366
5 54231548 rs2099082 T > C 23.6 ESM1 0.00 0.903 -0.01 0.767 0.01 0.853 0.00 0.957
5 157166116 rs10515754 T > C 6.0 CLINT1 0.06 0.293 0.05 0.422 0.10 0.086 0.10 0.082
6 91568115 rs9294466 A > T 15.0 MAP3K7 0.04 0.301 0.05 0.211 0.05 0.172 0.06 0.129
6 96483564 rs6925466 C > T 38.9 FUT9 0.00 0.870 0.00 0.888 -0.02 0.503 -0.02 0.493
7 14495103 rs7786503 A > C 8.0 DGKB 0.02 0.643 0.02 0.759 0.02 0.672 0.02 0.722
7 14497256 rs10499444 C > G 7.7 DGKB 0.01 0.869 -0.01 0.898 0.01 0.884 0.00 0.942
7 30896348 rs6462230 G > C 10.7 FLJ22374 0.04 0.396 0.06 0.221 0.02 0.732 0.03 0.485
7 147333625 rs2214681 G > A 42.5 CNTNAP2 0.00 0.950 -0.01 0.723 -0.01 0.798 -0.02 0.476
10 59991493 rs1649053 T > C 38.8 BICC1 -0.02 0.583 -0.01 0.829 -0.04 0.151 -0.03 0.324
10 127169837 rs10510144 G > A 28.9 MMP21 0.05 0.127 0.06 0.048 0.05 0.083 0.08 0.016
13 20860773 rs1409071 G > A 41.9 ZDHHC20 0.05 0.106 0.06 0.047 0.02 0.559 0.03 0.288
13 41736674 rs238358 G > A 9.5 AKAP11 0.03 0.536 0.03 0.516 -0.01 0.916 -0.01 0.896
13 92478066 rs10492621 G > A 24.2 GPC5 -0.06 0.068 -0.07 0.042 -0.07 0.035 -0.07 0.045
14 86696500 rs10513893 C > T 7.2 0.01 0.830 -0.01 0.821 0.04 0.449 0.03 0.551
16 26362052 rs8049649 A > T 17.6 HS3ST4 0.06 0.080 0.05 0.197 0.06 0.103 0.05 0.191
20 23097739 rs10485640 A > G 9.7 CD93 -0.05 0.274 -0.05 0.334 -0.05 0.273 -0.06 0.187
Chr: Chromosome, MAF: Minor allele frequency, BUA: Broadband ultrasound attenuation, SOS: Speed of sound, PASE: Physical activity scale for the elderly; b(SD),
effect estimates are shown as standardized values (standard deviations) for each copy of the minor allele.
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with 57% women whereas our population included 2377
men from seven countries across Europe. In addition,
using Bonferroni correction for the number of SNPs
tested in the Framingham study (N = 70,987), a p-value
< 7 × 10-7 would be required to reach genome-wide sig-
nificance level. However, none of the SNPs reached this
level possibly because of small sample size. We set our
cut off less stringently at p < 10-4 so that we would not
miss genuine associations. Therefore, there was a greater
chance that the selected SNPs were false positives due
to multiple testing. In addition, QUS is a less precise
method than DXA and shows higher within-subject
variability. There was also some evidence of between-
centre variability in the QUS parameters, which may
have reduced the likelihood of detecting true associa-
tions in EMAS.
Spurious results might have been produced in our
data due to factors such as population stratification. We
attempted to minimise population stratification by
excluding subjects of non-European ancestry and we did
not observed any heterogeneity of effect (by SNP centre
interaction). However, the country of origin was
assigned based on the subjects self-report and we were
unable to explore population substructure using meth-
ods such as genomic control or principal component
analysis as these require data on a large number of
SNPs. Therefore, we cannot exclude the possibility of
population stratification in our data.
Although the SNPs were selected based on their asso-
ciation with BUA and SOS, some of them were also
associated with BMD (p < 0.05) in the Framingham
study. In a sub-sample of our population (620 subjects)
for whom DXA measures were available, a single SNP,
rs238358, was associated with BMD at all three skeletal
sites (LS, FN and TH). The association between
rs238358 and FN BMD remained significant (p =
0.0009) even after applying a Bonferroni correction for
the number of independent SNPs (r2<0.8) (p < 0.0016
(0.05/31)). This SNP is located on chromosome 13,
about 8 Kb upstream of AKAP11 (A kinase anchor pro-
tein 11) and 35 Kb downstream of DGKH (diacylglycerol
kinase, eta) (Figure 2). This SNP was not associated with
BMD in the Framingham study but other SNPs in
AKAP11 have previously been associated with LS BMD
in a large-scale meta-analysis of GWAS at the genome-
wide significant level [20]. We did not find any evidence
in the literature connecting DGKH and bone
metabolism.
The SNP rs238358 is also located about 300 Kb
upstream of TNFSF11 (tumor necrosis factor
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111767814 111826604
Chromosome 1 position (hg18) (kb)
111534 111659 111784 111909 112034
0.0
0.2
0.4
0.6
0.8
1.0
R
-S
qu
ar
ed
0
20
40
60
80
R
ec
om
bi
na
tio
n 
ra
te
 (c
M
/M
b)
DENND2D
CHI3L2
CHIA C1orf88 OVGP1
WDR77
ATP5F1
C1orf162
ADORA3
RAP1A
Figure 1 Regional LD plot for rs3754032. The plot shows the linkage disequilibrium between rs3754032 and HapMap SNPs within 250 Kb,
recombination rate and the genes in the region using Annotation and Proxy Search (SNAP) (http://www.broadinstitute.org/mpg/snap/index.php).
The two dashed vertical lines show the location of HapMap SNPs which are in high LD (r2 ≥ 0.8) with rs3754032.
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superfamily, member 11) which encodes RANKL.
TNFSF11 is located beyond a recombination hot spot
and only modest LD (r2<0.2) exists between SNPs
within this gene and rs238358. Therefore, rs238358 is
unlikely to be a marker for a causal SNP within the
gene. However, the upstream region in which rs238358
is located may contain elements influencing TNFSF11
regulation. RANKL is a member of RANKL/RANK/
OPG signalling pathway which has an important role in
bone remodelling and has been associated with BMD at
the genome-wide significant level in GWAS [20-22] and
in the EMAS population previously [23].
The SNPs included in the Affymetrix 100K array used in
the Framingham GWAS have very limited tagging proper-
ties thus extensive areas of the genome were not ade-
quately evaluated in the GWAS. Using genome-wide SNP
chips with greater genome coverage in a large consortium
which combines data from multiple cohorts will enable
ascertainment of susceptibility loci for bone quality as
assessed by QUS parameters, similar to that which has
been carried out for DXA BMD at osteoporotic sites [20].
Conclusions
We observed suggestive evidence of association between
a single SNP located in the 3’UTR of WDR77 with the
calcaneal ultrasound parameter, SOS. This association
requires further validation in other independent popula-
tions. If this association is confirmed, fine mapping and
functional studies will be needed to identify the causal
variant. However, the majority of the SNPs associations
identified in the recent Framingham GWAS of bone
ultrasound phenotypes were not replicated in EMAS, an
independent population sample of men.
Additional material
Additional file 1: Supplementary Table S1: Genetic association
results from the Framingham 100K GWAS for SNPs selected for
genotyping.
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